Management focused on net sales, advertising expenses, and operating income
First written in FY2021. 6 of 11 entries say "Restated". Latest entry: FY2026.
46 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「客観的な指標として、売上高、EBITDAを重視しており、その中長期的な向上を図る経営に努めてまいります。また、当社事業モデルを勘案したうえでの重要な経営指標は、未病・予防期間の長期化、疾病期間の短縮化を実現する“SOKUYAKUヘルスケア経済圏”における活動人口を表す「QAU」、及び経済規模を示す「ARR」としております。」
売上高・EBITDA、QAU及びARRを重視する指標体系を継続している。 - 2026-07-15RestatedEarnings
「To achieve this mission, we regard QAU (Note 1), which represents the active population in the SOKUYAKU healthcare ecosystem, and ARR (Note 2), which represents its economic scale, as important management indicators and will swiftly implement every measure to increase them.」
QAU及びARRを重要な経営指標とする説明を再確認している。 - FY2026-H1RestatedAnnual report
「There have been no material changes during the current interim consolidated accounting period to the management policies, management strategies and other matters established by the Group, or to the objective indicators used to assess progress toward management targets.」
売上高・EBITDA、QAU及びARRを重視する指標体系について、重要な変更がないと再確認している。 - FY2024ReframedAnnual report
「As objective metrics, we place importance on revenue and EBITDA and will manage the business to improve them over the medium to long term. In light of our business model, our key management metrics are QAU, which represents the active population in the SOKUYAKU healthcare ecosystem that extends the pre-disease and prevention period and shortens the disease period, and ARR, which represents its economic scale.」
The company has shifted from emphasizing revenue, advertising expense and operating profit to a framework centered on revenue and EBITDA, together with QAU and ARR for the SOKUYAKU healthcare ecosystem. - FY2024-Q3RestatedAnnual report
「更なる会員獲得のための地上波テレビコマーシャルのリニューアルなど、戦略的な広告施策を推進いたしました。」
SOKUYAKUの会員獲得に向けた地上波テレビCM等の広告施策を継続している。 - FY2023RestatedAnnual report
「客観的な指標として、売上高、広告宣伝費、営業利益を重視しており、その中長期的な向上を図る経営に努めてまいります。」
売上高・広告宣伝費・営業利益のバランスを重視する経営指標の方針を継続している。 - FY2023-Q1RestatedAnnual report
「新規顧客の獲得効率やLTV（Life Time Value：顧客生涯価値）が高い第１類医薬品や生漢煎®防風通聖散等の第２類医薬品に対して、戦略的に広告費を集中投下したことにより、医薬品の販売が好調に推移いたしました。」
新規顧客獲得効率とLTVを重視し、医薬品に広告費を集中する運用を継続している。 - FY2022AdvancedAnnual report
「In the fiscal year ended May 2022, revenue was ¥11,876,681 thousand, advertising expenses were ¥2,410,545 thousand and operating profit was ¥732,239 thousand.」
The Company disclosed fiscal-year 2022 results for revenue, advertising expenses and operating profit, demonstrating continued management of both advertising investment and profit levels. - FY2022-Q3AdvancedAnnual report
「新規顧客の獲得効率やLTV（Life Time Value：顧客生涯価値）が高い第１類医薬品や生漢煎防風通聖散等の第２類医薬品に対して、戦略的に広告費を集中投下した」
新規顧客獲得効率と顧客生涯価値を基準に、医薬品へ広告費を重点配分する具体的な運用を行った。 - FY2022-Q1AdvancedAnnual report
「We place importance on management metrics relating to the cost of acquiring new customers and took measures such as refraining from purchasing advertising inventory whose prices had been driven up by market conditions.」
The policy of balancing advertising expenses and operating profit is reflected in the specific decision to refrain from acquiring overpriced advertising inventory based on customer-acquisition costs. - FY2021First statedAnnual report
「As objective metrics, we place importance on revenue, advertising expense and operating profit, and will manage the business to balance and optimize these metrics.」
The company emphasizes balancing advertising expense as a growth investment with operating profit as a measure of profitability.